This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer, Merck: Tomorrow's Headliners

NEW YORK ( TheStreet) -- Merck (MRK - Get Report) and Pfizer (PFE - Get Report) will be in focus Tuesday as both components of the Dow Jones Industrial Average will post earnings results.

Merck should report a first-quarter profit of 75 cents a share on revenue of $11.17 billion, according to a Thomson Reuters poll of estimates. That would be a penny higher than its profit in the first quarter of 2009.

Meanwhile, fellow drugmaker Pfizer should see first-quarter earnings of 53 cents a share on revenue of $16.57 billion. Unlike Merck, that would be a penny below its year-ago profit. Investors should watch for the contributions from the Schering-Plough acquisition, which has boosted revenue but done little to affect bottom-line growth.

Several other companies will report quarterly results before the start of trading Tuesday, including Archer-Daniels Midland (ADM - Get Report), CVS Caremark (CVS - Get Report), Mastercard (MA - Get Report), Marathon Oil (MRO - Get Report), and Sirius XM (SIRI - Get Report).

On the economic front, separate reports on factory orders and pending home sales will be released at 10 a.m. ET. Economists expect the latest factory orders report to show a 0.2% decline in March after a 0.6% rise in February.

Meanwhile, the National Association of Realtors will likely say that pending home sales rose 5% in March, according to a survey of analysts, which follows an 8.2% increase in February.

-- Written by Robert Holmes in Boston.

Follow Robert Holmes on Twitter and become a fan of on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ADM $40.22 0.70%
CVS $101.48 0.98%
MA $97.71 0.74%
MRO $13.54 -3.90%
MRK $55.31 0.86%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,082.49 +17.19 0.83%
NASDAQ 4,819.3120 +43.9540 0.92%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs